East China Pharmaceutical: The application for listing in Ibufen Tablets has been accepted.

East China Pharmaceutical announced that the market approval application for the oral Dilara tablets for the treatment of acute ischemic stroke, submitted by its wholly-owned subsidiary Sino-American East China, has been accepted by the National Medical Products Administration. Dilara tablets are a new type of free radical scavenger aimed at improving the neurological symptoms and functional impairments of stroke patients. Compared to the existing Dilara injection, the oral tablets are more convenient for patients to self-administer. Sino-American East has signed an exclusive license agreement with Auspex Biotech, obtaining the rights for the development, registration, production, and commercialization of the drug in mainland China, Hong Kong, Macau, and Taiwan. As of now, the company has invested approximately 101 million yuan in this project, including an initial payment of 100 million yuan.